M40 (trifluoroacetate salt)
(Synonyms: Galanin-(1-12)-Pro3-(Ala-Leu)2-Ala amide) 目录号 : GC91855M40 is a chimeric galanin-derived peptide and galanin-1 (GAL1) receptor antagonist and GAL2 receptor agonist (Kis = 2.4 and 4.07 nM, respectively).
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
M40 is a chimeric galanin-derived peptide and galanin-1 (GAL1) receptor antagonist and GAL2 receptor agonist (Kis = 2.4 and 4.07 nM, respectively).[1],[2] It is selective for the GAL1 and GAL2 receptors over the GAL3 receptor (Ki = 288 nM).[1] M40 induces inositol phosphate accumulation in CHO cells expressing the human GAL2 receptor (EC50 = 16.2 nM) and inhibits forskolin-induced cAMP accumulation in RIN-m5F pancreatic β-cells when used at concentrations of 10 or 100 nM.[1],[2] In vivo, M40 (9.36 nmol/animal, i.c.v.) reverses galanin-induced inhibition of scopolamine-induced hippocampal acetylcholine (ACh) release in conscious rats.[2] M40 reduces galanin-induced increases in food intake in rats. It improves cardiac function and decreases cardiac fibrosis in a rat model of heart failure induced by sustained coronary artery ligation when administered at a dose of 30 nmol/kg.[3] M40 (20 µg/animal) increases the intromission frequency and ejaculation latency in sexually sluggish male mice.[4]
References:
[1].Borowsky, B., Walker, M.W., Huang, L.Y., et al.Cloning and characterization of the human galanin GALR2 receptorPeptides19(10)1771-1781(1998).
[2].Bartfai, T., Langel, Ü., Bedecs, K., et al.Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypesProc. Natl. Acad. Sci. USA90(23)11287-11291(1993).
[3].Chen, A., Li, M., Song, L., et al.Effects of the galanin receptor antagonist M40 on cardiac function and remodeling in rats with heart failureCardiovasc. Ther.33(5)288-293(2015).
[4].Benelli, A., Bertolini, A., Zoli, M., et al.Pharmacological manipulation of brain galaninergic system and sexual behavior in male micePsychopharmacology (Berl)160(3)325-330(2002).
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5047 mL | 2.5236 mL | 5.0472 mL |
| 5 mM | 0.1009 mL | 0.5047 mL | 1.0094 mL |
| 10 mM | 0.0505 mL | 0.2524 mL | 0.5047 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。